Compare CRL & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | FDS |
|---|---|---|
| Founded | 1947 | 1978 |
| Country | United States | United States |
| Employees | N/A | 6258 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 9.1B |
| IPO Year | 1999 | 1996 |
| Metric | CRL | FDS |
|---|---|---|
| Price | $260.72 | $278.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | $198.27 | ★ $284.80 |
| AVG Volume (30 Days) | ★ 786.4K | 764.7K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | ★ 1.89% |
| EPS Growth | N/A | ★ 11.79 |
| EPS | N/A | ★ 11.16 |
| Revenue | ★ $1,857,601,000.00 | $1,435,351,000.00 |
| Revenue This Year | N/A | $7.16 |
| Revenue Next Year | $3.04 | $5.55 |
| P/E Ratio | ★ N/A | $24.60 |
| Revenue Growth | ★ 10.48 | 6.31 |
| 52 Week Low | $144.26 | $185.00 |
| 52 Week High | $242.73 | $396.06 |
| Indicator | CRL | FDS |
|---|---|---|
| Relative Strength Index (RSI) | 72.25 | 60.39 |
| Support Level | $153.47 | $267.36 |
| Resistance Level | N/A | $300.77 |
| Average True Range (ATR) | 8.53 | 11.31 |
| MACD | 0.51 | 1.05 |
| Stochastic Oscillator | 77.93 | 64.50 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.